Manufacturers of Androgel Want Coordination of Federal and State Testosterone Lawsuits

Chicago, Illinois—In June, all testosterone therapy lawsuits previously filed in various federal courts throughout the United States were consolidated in a single court – the U.S. District Court for the Northern District of Illinois.  The advantages of consolidation include efficiency, resource conservation, reduction of duplication in the trial preparation process and elimination of the possibility of conflicting rulings among different courts. 

This consolidation is referred to as “multidistrict litigation (MDL),” and it is widely used when many cases are filed in federal courts that share common issues, as those involving claims for failure to adequately inform doctors and patients of the cardiovascular risks of taking low-t therapy drugs.

Now, AbbVie and Abbott Laboratories, manufacturers of the testosterone therapy drug AndroGel, are seeking to coordinate the federal MDL litigation with lawsuits pending against them in various state courts.

The Illinois District Court has yet to rule on the coordination request, or determine the operational details of any such plan.

Testosterone therapy drug brands include AndroGel, AndroDerm, Axiron, Bio-T-Gel, Delatestryl, Depo-Testosterone, Fortesta, Striant, Testim, Testopel.